Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate
© Ahmed et al.; licensee BioMed Central Ltd. 2013
Received: 22 May 2013
Accepted: 25 September 2013
Published: 4 November 2013
Anemia in end stage renal disease is attributed to impaired erythrocyte formation due to erythropoietin and iron deficiency. On the other hand, end stage renal disease enhances eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and phosphatidylserine-exposure at the erythrocyte surface. Eryptosis may be triggered by increase of cytosolic Ca2+-activity ([Ca2+]i) and by ceramide, which sensitizes erythrocytes to [Ca2+]i. Mechanisms triggering eryptosis in endstage renal disease remained enigmatic. The present study explored the effect of indoxyl sulfate, an uremic toxin accumulated in blood of patients with chronic kidney disease.
Cell volume was estimated from forward scatter, phosphatidylserine-exposure from annexin V binding, ceramide abundance by specific antibodies, hemolysis from hemoglobin release, and [Ca2+]i from Fluo3-fluorescence.
A 48 hours exposure to indoxyl sulfate significantly increased [Ca2+]i (≥ 300 μM), significantly decreased forward scatter (≥ 300 μM) and significantly increased annexin-V-binding (≥ 50 μM). Indoxyl sulfate (150 μM) induced annexin-V-binding was virtually abolished in the nominal absence of extracellular Ca2+. Indoxyl sulfate (150 μM) further enhanced ceramide abundance.
Indoxyl sulfate stimulates suicidal erythrocyte death or eryptosis, an effect in large part due to stimulation of extracellular Ca2+entry with subsequent stimulation of cell shrinkage and cell membrane scrambling.
KeywordsPhosphatidylserine Indoxyl sulfate Calcium Cell volume Eryptosis
Severe complications of end stage renal disease include anemia [1, 2], which is at least in part the result of restricted renal erythropoietin release and subsequent impairment of erythropoiesis [3, 4]. In end stage renal disease erythropoiesis is typically further compromized by iron deficiency [5, 6]. In addition, compelling evidence points to accelerated clearance of circulating erythrocytes in end stage renal disease . The accelerated clearance of erythrocytes in end stage renal disease may at least partially be due to enhanced eryptosis, a suicidal death of erythrocytes characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine exposure at the erythrocyte surface [8, 9]. As a matter of fact, the concentration of phosphatidylserine exposing erythrocytes has been found to be twice as high in patients on dialysis than in the common population . As phosphatidylserine exposing erythrocytes are rapidly cleared from circulating blood in vivo , a doubling of phosphatiylserine exposing erythrocytes in circulating blood is expected to reflect a decrease of erythrocyte life span to half. As long as erythrocyte formation is not enhanced, a decrease of erythrocyte life span would lead to a quantitatively similar decrease of erythrocyte count in circulating blood. Thus, the contribution of eryptosis to anemia in CKD patients is probably substantial.
The most important trigger of eryptosis is enhanced cytosolic Ca2+ concentration ([Ca2+]i) [8, 9]. The increase of [Ca2+]i may result from Ca2+ entry through Ca2+-permeable cation channels , which are activated by oxidation . Increased [Ca2+]i leads to eryptotic cell shrinkage by activation of Ca2+-sensitive K+ channels , K+ exit, hyperpolarization, Cl- exit and thus cellular KCl and water loss . Increased [Ca2+]i triggers phosphatidylserine exposure at the cell surface by triggering cell membrane scrambling . Eryptosis may further be stimulated by ceramide , energy depletion , caspase activation [9, 11, 12] and deranged activity of kinases such as protein kinase C , AMP activated kinase AMPK , cGMP-dependent protein kinase , Janus-activated kinase JAK3 , casein kinase [14, 15], p38 kinase , as well as sorafenib  and sunitinib  sensitive kinases. Eryptosis is further triggered by a wide variety of xenobiotics and is enhanced in a variety of clinical disorders [9, 19–37].
Little is known about mechanisms underlying enhanced eryptosis in endstage renal disease. At least in theory, eryptosis may be stimulated by some uremic toxins. As a matter of fact, eryptosis has previously been shown to be triggered by the uremic toxins vanadate , acrolein  and methylglyoxal . A further uremic toxins that could contribute to anemia in chronic kidney disease is indoxyl sulfate [39, 40], which is at least partially effective by suppression of erythropoietin production . Further effects of indoxyl sulfate include downregulation of Klotho , induction of oxidative stress [42, 43], up-regulation of NFκB , aortic calcification and aortic wall thickening , interference with wound repair , triggering of cell senescence , stimulation of cardiac and renal fibrosis [42, 45] and acceleration of renal disease progression . Indoxyl sulfate is generated by colonic microbes  and accumulates in blood, if renal excretion is impaired . Indoxyl sulfate induces apoptosis, the suicidal death of nucleated cells, an effect involving ERK1/2 and p38 MAP kinase .
The present study explored, whether eryptosis is stimulated by indoxyl sulfate. To this end, the effect of indoxyl sulfate on [Ca2+]i, cell volume, ceramide formation and phosphatidylserine abundance at the erythrocyte surface were determined.
Erythrocytes, solutions and chemicals
Leukocyte-depleted erythrocytes were kindly provided by the blood bank of the University of Tübingen. The study is approved by the ethics committee of the University of Tübingen (184/2003 V). Erythrocytes were incubated in vitro at a hematocrit of 0.4% in Ringer solution containing (in mM) 125 NaCl, 5 KCl, 1 MgSO4, 32 N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid (HEPES), 5 glucose, 1 CaCl2; pH 7.4 at 37°C for 48 h. Where indicated, erythrocytes were exposed to indoxyl sulfate potassium salt (Sigma-Aldrich, Steinheim, Germany) at the indicated concentrations. In Ca2+-free Ringer solution, 1 mM CaCl2 was substituted by 1 mM glycol-bis(2-aminoethylether)-N,N,N’,N’-tetraacetic acid (EGTA).
FACS analysis of annexin-V-binding and forward scatter
After incubation under the respective experimental condition, 50 μl cell suspension was washed in Ringer solution containing 5 mM CaCl2 and then stained with Annexin-V-FITC (1:200 dilution; ImmunoTools, Friesoythe, Germany) in this solution at 37°C for 20 min under protection from light. In the following, the forward scatter (FSC) of the cells was determined, and annexin-V fluorescence intensity was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur (BD, Heidelberg, Germany).
Measurement of intracellular Ca2+
After incubation erythrocytes were washed in Ringer solution and then loaded with Fluo-3/AM (Biotium, Hayward, USA) in Ringer solution containing 5 mM CaCl2 and 2 μM Fluo-3/AM. The cells were incubated at 37°C for 30 min and washed twice in Ringer solution containing 5 mM CaCl2. The Fluo-3/AM-loaded erythrocytes were resuspended in 200 μl Ringer. Then, Ca2+-dependent fluorescence intensity was measured with an excitation wavelength of 488 nm and an emission wavelength of 530 nm on a FACS Calibur.
Measurement of hemolysis
For the determination of hemolysis the samples were centrifuged (3 min at 400 g, room temperature) after incubation, and the supernatants were harvested. As a measure of hemolysis, the hemoglobin (Hb) concentration of the supernatant was determined photometrically at 405 nm. The absorption of the supernatant of erythrocytes lysed in distilled water was defined as 100% hemolysis.
Determination of ceramide formation
For the determination of ceramide, a monoclonal antibody-based assay was used. After incubation, cells were stained for 1 hour at 37°C with 1 μg/ml anti-ceramide antibody (clone MID 15B4, Alexis, Grünberg, Germany) in PBS containing 0.1% bovine serum albumin (BSA) at a dilution of 1:5. The samples were washed twice with PBS-BSA. Subsequently, the cells were stained for 30 minutes with polyclonal fluorescein-isothiocyanate (FITC)-conjugated goat anti-mouse IgG and IgM specific antibody (Pharmingen, Hamburg, Germany) diluted 1:50 in PBS-BSA. Unbound secondary antibody was removed by repeated washing with PBS-BSA. The samples were then analyzed by flow cytometric analysis with an excitation wavelength of 488 nm and an emission wavelength of 530 nm.
Data are expressed as arithmetic means ± SEM. As indicated in the figure legends, statistical analysis was made using ANOVA and t test as appropriate. N denotes the number of different erythrocyte specimens studied. Since different erythrocyte specimens used in distinct experiments are differently susceptible to triggers of eryptosis, the same erythrocyte specimens have been used for control and experimental conditions.
Results and discussion
To explore, whether indoxyl sulfate exposure leads to hemolysis, the percentage of hemolysed erythrocytes was quantified by determination of hemoglobin abundance in the supernatant. As shown in Figure 2, treatment of erythrocytes for 48 hours with indoxyl sulfate did not significantly increase the hemoglobin concentration in the supernatant. (Figure 2). Thus, indoxyl sulfate triggered phosphatidylserine translocation at the cell membrane without appreciably permeabilizing the cell membrane to hemoglobin.
The present study uncovers a novel effect of indoxyl sulfate, i.e. the triggering of erythrocyte shrinkage and erythrocyte cell membrane scrambling, both hallmarks of suicidal erythrocyte death or eryptosis. The concentrations of indoxyl sulfate required for statistically significant stimulation of eryptosis were in the range of those encountered in uremic plasma [39, 48].
The observed erythrocyte shrinkage following indoxyl sulfate treatment presumably resulted from increase of cytosolic Ca2+ concentration with subsequent activation of Ca2+ sensitive K+ channels [9, 49], K+ exit, cell membrane hyperpolarisation, Cl- exit and thus cellular loss of KCl with osmotically obliged water .
The observed indoxyl sulfate induced cell membrane scrambling was similarly due to increased cytosolic Ca2+ activity. Accordingly, the presence of extracellular Ca2+ is required for full stimulation of cell membrane scrambling. The indoxyl sulfate concentrations required to trigger phosphatidylserine exposure were lower than those required to significantly enhance Fluo3 fluorescence and to decrease forward scatter. It must be kept in mind that Fluo3 fluorescence and forward scatter may be less sensitive than detection of annexin V binding erythrocytes. Thus, the present observations do not allow the conclusion that Ca2+ independent stimulation of cell membrane scrambling does occur at low indoxyl sulfate concentrations. Nevertheless, additional mechanisms may conctribute to the stimulation of cell membrane scrambling following indoxyl sulfate exposure. As shown here, indoxyl sulfate stimulates the formation of ceramide, which is in turn known to sensitize erythrocytes for the scrambling effects of increased cytosolic Ca2+ concentration . Indoxyl sulfate induces oxidative stress [42, 43], a well known trigger of eryptosis [9, 12]. Indoxyl sulfate further activates p38 MAP kinase , which again has been shown to trigger eryptosis . Moreover, the machinery governing eryptosis includes caspases [9, 11, 12], protein kinase C , AMP activated kinase AMPK , cGMP-dependent protein kinase , Janus-activated kinase JAK3  and casein kinase [14, 15]. At least in theory, those mechanisms may participate in the triggering of eryptosis by indoxyl sulfate.
Indoxyl sulfate is an uremic toxin, which could well contribute to the accelerated erythrocyte death in end stage renal disease. Phosphatidylserine exposing erythrocytes are bound to phagocytosing cells and are thus rapidly cleared from circulating blood . In end stage renal disease, the accelerated loss of erythrocytes is paralleled by impaired formation of new erythrocytes thus leading to development of anemia . The effect of indoxyl sulfate could be shared by other uremic toxins, which could similarly trigger eryptosis. Uremic toxins already known to trigger eryptosis include vanadate , acrolein  and methylglyoxal . Moreover, eryptosis and thus clearance of affected erythrocytes from circulating blood is stimulated by iron deficiency , which is common in end stage renal disease and contributes to the development of anemia in those patients [5,6]. Clearly, additional substances or disorders could contribute to the development of anemia in patients with end stage renal disease.
Excessive eryptosis in end stage renal disease could further trigger thrombosis and impede microcirculation. Phosphatidylserine exposing erythrocytes adhere to the vascular wall at least in part by interaction of the erythrocyte phosphatidylserine and endothelial CXCL16/SR-PSO . Erythrocyte adherence to the vascular wall is expected to interfere with blood flow [9, 52]. Phosphatidylserine exposing erythrocytes may further stimulate blood clotting [9, 53, 54]. The curtailing of blood flow following enhanced turnover of erythrocytes with increased numbers of phosphatidylserine exposing erythrocytes in circulating blood may contribute to the side effects following uncritical use of erythropoietin or other erythropoiesis stimulating agents [55–57].
The uremic toxin indoxyl sulfate triggers cell shrinkage and cell membrane scrambling and thus eryptosis, the suicidal death of erythrocytes. Indoxyl sulfate is at least partially effective by increasing cytosolic Ca2+ and ceramide formation.
The study was supported by the Deutsche Forschungsgemeinschaft.
- Yang M, Fox CH, Vassalotti J, Choi M: Complications of progression of CKD. Adv Chronic Kidney Dis. 2011, 18 (6): 400-405. 10.1053/j.ackd.2011.10.001.View ArticlePubMedGoogle Scholar
- Dmitrieva O, de Lusignan S, Macdougall IC, Gallagher H, Tomson C, Harris K, Desombre T, Goldsmith D: Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC nephrology. 2013, 14: 24-10.1186/1471-2369-14-24.View ArticlePubMedPubMed CentralGoogle Scholar
- Atkinson MA, Furth SL: Anemia in children with chronic kidney disease. Nat Rev Nephrol. 2011, 7 (11): 635-641. 10.1038/nrneph.2011.115.View ArticlePubMedGoogle Scholar
- Parfrey PS: Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. Curr Opin Nephrol Hypertens. 2011, 20 (2): 177-181. 10.1097/MNH.0b013e3283428bc2.View ArticlePubMedGoogle Scholar
- Kwack C, Balakrishnan VS: Managing erythropoietin hyporesponsiveness. Semin Dial. 2006, 19 (2): 146-151. 10.1111/j.1525-139X.2006.00141.x.View ArticlePubMedGoogle Scholar
- Kovesdy CP: Iron and clinical outcomes in dialysis and non-dialysis-dependent chronic kidney disease patients. Adv Chronic Kidney Dis. 2009, 16 (2): 109-116. 10.1053/j.ackd.2008.12.006.View ArticlePubMedGoogle Scholar
- Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ: Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011, 58 (4): 591-598. 10.1053/j.ajkd.2011.03.031.View ArticlePubMedGoogle Scholar
- Nguyen DB, Wagner-Britz L, Maia S, Steffen P, Wagner C, Kaestner L, Bernhardt I: Regulation of phosphatidylserine exposure in red blood cells. Cell Physiol Biochem. 2011, 28 (5): 847-856. 10.1159/000335798.View ArticlePubMedGoogle Scholar
- Lang E, Qadri SM, Lang F: Killing me softly - suicidal erythrocyte death. Int J Biochem Cell Biol. 2012, 44 (8): 1236-1243. 10.1016/j.biocel.2012.04.019.View ArticlePubMedGoogle Scholar
- Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F: Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol. 2003, 14 (11): 2750-2757. 10.1097/01.ASN.0000093253.42641.C1.View ArticlePubMedGoogle Scholar
- Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB- and PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology. 2012, 6: 847-56. 10.3109/17435390.2011.625132. doi:10.3109/17435390.2011.625132. Epub 2011 Oct 24View ArticlePubMedGoogle Scholar
- Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol. 2013, 50 (4): 489-95. 10.1007/s00592-011-0274-0. doi:10.1007/s00592-011-0274-0. Epub 2011 Mar 25View ArticlePubMedGoogle Scholar
- Bhavsar SK, Gu S, Bobbala D, Lang F: Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Cell Physiol Biochem. 2011, 27 (5): 547-556. 10.1159/000329956.View ArticlePubMedGoogle Scholar
- Zelenak C, Eberhard M, Jilani K, Qadri SM, Macek B, Lang F: Protein kinase CK1alpha regulates erythrocyte survival. Cell Physiol Biochem. 2012, 29 (1–2): 171-180.View ArticlePubMedGoogle Scholar
- Kucherenko YV, Huber SM, Nielsen S, Lang F: Decreased redox-sensitive erythrocyte cation channel activity in aquaporin 9-deficient mice. J Membr Biol. 2012, 245 (12): 797-805. 10.1007/s00232-012-9482-y. doi:10.1007/s00232-012-9482-y. Epub 2012 Jul 27View ArticlePubMedGoogle Scholar
- Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Lang F: p38 MAPK activation and function following osmotic shock of erythrocytes. Cell Physiol Biochem. 2011, 28 (6): 1279-1286. 10.1159/000335859.View ArticlePubMedGoogle Scholar
- Lupescu A, Shaik N, Jilani K, Zelenak C, Lang E, Pasham V, Zbidah M, Plate A, Bitzer M, Foller M, et al: Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study. Cell Physiol Biochem. 2012, 30 (4): 876-888. 10.1159/000341465.View ArticlePubMedGoogle Scholar
- Shaik N, Lupescu A, Lang F: Sunitinib-sensitive suicidal erythrocyte death. Cell Physiol Biochem. 2012, 30 (3): 512-522. 10.1159/000341434.View ArticlePubMedGoogle Scholar
- Shaik N, Zbidah M, Lang F: Inhibition of Ca(2+) entry and suicidal erythrocyte death by naringin. Cell Physiol Biochem. 2012, 30 (3): 678-686. 10.1159/000341448.View ArticlePubMedGoogle Scholar
- Zelenak C, Pasham V, Jilani K, Tripodi PM, Rosaclerio L, Pathare G, Lupescu A, Faggio C, Qadri SM, Lang F: Tanshinone IIA stimulates erythrocyte phosphatidylserine exposure. Cell Physiol Biochem. 2012, 30 (1): 282-294. 10.1159/000339064.View ArticlePubMedGoogle Scholar
- Qadri SM, Kucherenko Y, Zelenak C, Jilani K, Lang E, Lang F: Dicoumarol activates Ca2 + -permeable cation channels triggering erythrocyte cell membrane scrambling. Cell Physiol Biochem. 2011, 28 (5): 857-864. 10.1159/000335800.View ArticlePubMedGoogle Scholar
- Qadri SM, Bauer J, Zelenak C, Mahmud H, Kucherenko Y, Lee SH, Ferlinz K, Lang F: Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. Cell Physiol Biochem. 2011, 28 (2): 339-346. 10.1159/000331750.View ArticlePubMedGoogle Scholar
- Lang E, Jilani K, Zelenak C, Pasham V, Bobbala D, Qadri SM, Lang F: Stimulation of suicidal erythrocyte death by benzethonium. Cell Physiol Biochem. 2011, 28 (2): 347-354. 10.1159/000331751.View ArticlePubMedGoogle Scholar
- Ghashghaeinia M, Toulany M, Saki M, Bobbala D, Fehrenbacher B, Rupec R, Rodemann HP, Ghoreschi K, Rocken M, Schaller M, et al: The NFkB pathway inhibitors Bay 11–7082 and parthenolide induce programmed cell death in anucleated erythrocytes. Cell Physiol Biochem. 2011, 27 (1): 45-54. 10.1159/000325204.View ArticlePubMedGoogle Scholar
- Felder KM, Hoelzle K, Ritzmann M, Kilchling T, Schiele D, Heinritzi K, Groebel K, Hoelzle LE: Hemotrophic mycoplasmas induce programmed cell death in red blood cells. Cell Physiol Biochem. 2011, 27 (5): 557-564. 10.1159/000329957.View ArticlePubMedGoogle Scholar
- Jilani K, Lupescu A, Zbidah M, Abed M, Shaik N, Lang F: Enhanced apoptotic death of erythrocytes induced by the mycotoxin ochratoxin a. Kidney Blood Press Res. 2012, 36 (1): 107-118. 10.1159/000341488.View ArticlePubMedGoogle Scholar
- Polak-Jonkisz D, Purzyc L: Ca influx versus efflux during eryptosis in uremic erythrocytes. Blood Purif. 2012, 34 (3–4): 209-210.View ArticlePubMedGoogle Scholar
- Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F: Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol. 2012, 303 (9): C991-999. 10.1152/ajpcell.00239.2012.View ArticlePubMedGoogle Scholar
- Vota DM, Maltaneri RE, Wenker SD, Nesse AB, Vittori D: Differential erythropoietin action upon cells induced to eryptosis by different agents. Cell Biochem Biophys. 2013, 65 (2): 145-57. 10.1007/s12013-012-9408-4. doi:10.1007/s12013-012-9408-4View ArticlePubMedGoogle Scholar
- Firat U, Kaya S, Cim A, Buyukbayram H, Gokalp O, Dal MS, Tamer MN: Increased caspase-3 immunoreactivity of erythrocytes in STZ diabetic rats. Exp Diabetes Res. 2012, 2012: 316384-View ArticlePubMedPubMed CentralGoogle Scholar
- Bottger E, Multhoff G, Kun JF, Esen M: Plasmodium falciparum-infected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70. PLoS One. 2012, 7 (3): e33774-10.1371/journal.pone.0033774.View ArticlePubMedPubMed CentralGoogle Scholar
- Ghashghaeinia M, Cluitmans JC, Akel A, Dreischer P, Toulany M, Koberle M, Skabytska Y, Saki M, Biedermann T, Duszenko M, et al: The impact of erythrocyte age on eryptosis. Br J Haematol. 2012, 157 (5): 606-614. 10.1111/j.1365-2141.2012.09100.x.View ArticlePubMedGoogle Scholar
- Gao M, Cheung KL, Lau IP, Yu WS, Fung KP, Yu B, Loo JF, Kong SK: Polyphyllin D induces apoptosis in human erythrocytes through Ca(2)(+) rise and membrane permeabilization. Arch Toxicol. 2012, 86 (5): 741-752. 10.1007/s00204-012-0808-4.View ArticlePubMedGoogle Scholar
- Ganesan S, Chaurasiya ND, Sahu R, Walker LA, Tekwani BL: Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology. 2012, 294 (1): 54-60. 10.1016/j.tox.2012.01.015.View ArticlePubMedGoogle Scholar
- Weiss E, Cytlak UM, Rees DC, Osei A, Gibson JS: Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. Cell Calcium. 2012, 51 (1): 51-56. 10.1016/j.ceca.2011.10.005.View ArticlePubMedGoogle Scholar
- Lupescu A, Jilani K, Zelenak C, Zbidah M, Shaik N, Lang F: Induction of programmed erythrocyte death by gambogic acid. Cell Physiol Biochem. 2012, 30 (2): 428-438. 10.1159/000339036.View ArticlePubMedGoogle Scholar
- Kucherenko YV, Lang F: Inhibitory effect of furosemide on Non-selective voltage-independent cation channels in human erythrocytes. Cell Physiol Biochem. 2012, 30 (4): 863-875. 10.1159/000341464.View ArticlePubMedGoogle Scholar
- Ahmed M, Langer H, Abed M, Voelkl J, Lang F: The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res. 2013, 37: 158-167. 10.1159/000350141.View ArticlePubMedGoogle Scholar
- Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012, 23 (7): 1258-1270. 10.1681/ASN.2011121175.View ArticlePubMedPubMed CentralGoogle Scholar
- Bolati D, Shimizu H, Yisireyili M, Nishijima F, Niwa T: Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-kappaB. BMC nephrology. 2013, 14: 56-10.1186/1471-2369-14-56.View ArticlePubMedPubMed CentralGoogle Scholar
- Chiang CK, Tanaka T, Inagi R, Fujita T, Nangaku M: Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011, 91 (11): 1564-1571. 10.1038/labinvest.2011.114.View ArticlePubMedGoogle Scholar
- Niwa T, Shimizu H: Indoxyl sulfate induces nephrovascular senescence. J Ren Nutr. 2012, 22 (1): 102-106. 10.1053/j.jrn.2011.10.032.View ArticlePubMedGoogle Scholar
- Schmid U, Stopper H, Heidland A, Schupp N: Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev. 2008, 24 (5): 371-377. 10.1002/dmrr.860.View ArticlePubMedGoogle Scholar
- Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, Berland Y, Brunet P: The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int. 2004, 65 (2): 442-451. 10.1111/j.1523-1755.2004.00399.x.View ArticlePubMedGoogle Scholar
- Liu S, Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H: Cardiorenal syndrome: pathophysiology, preclinical models, management and potential role of uraemic toxins. Clin Exp Pharmacol Physiol. 2012, 39 (8): 692-700. 10.1111/j.1440-1681.2011.05632.x.View ArticlePubMedGoogle Scholar
- Meyer TW, Hostetter TH: Uremic solutes from colon microbes. Kidney Int. 2012, 81 (10): 949-954. 10.1038/ki.2011.504.View ArticlePubMedGoogle Scholar
- Kim SH, Yu MA, Ryu ES, Jang YH, Kang DH: Indoxyl sulfate-induced epithelial-to-mesenchymal transition and apoptosis of renal tubular cells as novel mechanisms of progression of renal disease. Lab Invest. 2012, 92 (4): 488-498. 10.1038/labinvest.2011.194.View ArticlePubMedGoogle Scholar
- Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA: Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009, 4 (10): 1551-1558. 10.2215/CJN.03980609.View ArticlePubMedPubMed CentralGoogle Scholar
- Bookchin RM, Ortiz OE, Lew VL: Activation of calcium-dependent potassium channels in deoxygenated sickled red cells. Prog Clin Biol Res. 1987, 240: 193-200.PubMedGoogle Scholar
- Lang F, Gulbins E, Lerche H, Huber SM, Kempe DS, F"ller M: Eryptosis, a window to systemic disease. Cell Physiol Biochem. 2008, 22 (5–6): 373-380.View ArticlePubMedGoogle Scholar
- Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F: Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J. 2006, 20 (2): 368-370.PubMedGoogle Scholar
- Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F: Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol. 2012, 302 (4): C644-C651. 10.1152/ajpcell.00340.2011.View ArticlePubMedGoogle Scholar
- Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol. 2007, 27 (2): 414-421.View ArticlePubMedGoogle Scholar
- Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci. 2005, 62 (9): 971-988. 10.1007/s00018-005-4527-3.View ArticlePubMedGoogle Scholar
- Singh AK: What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?. Curr Opin Nephrol Hypertens. 2010, 19 (5): 420-424. 10.1097/MNH.0b013e32833cf1d6.View ArticlePubMedGoogle Scholar
- Elliott J, Mishler D, Agarwal R: Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis. 2009, 16 (2): 94-100. 10.1053/j.ackd.2008.12.004.View ArticlePubMedGoogle Scholar
- Kalantar-Zadeh K, Streja E, Miller JE, Nissenson AR: Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?. Adv Chronic Kidney Dis. 2009, 16 (2): 143-151. 10.1053/j.ackd.2008.12.008.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/14/244/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.